ImmunityBio (IBRX Stock): 700% Revenue Explosion & The Global Expansion Hasn’t Even Started

Описание: ImmunityBio (IBRX Stock): 700% Revenue Explosion & The Global Expansion Hasn’t Even Started

$IBRX, IBRX, ImmunityBio stock, immunity bio stock, ImmunityBio,

ImmunityBio (IBRX) has delivered explosive 700% year-over-year revenue growth driven by strong U.S. adoption of ANKTIVA for BCG-unresponsive NMIBC bladder cancer, marking a major shift from development-stage biotech to commercial-stage immunotherapy company. With regulatory approvals now secured across 33 countries — including the United States, United Kingdom, European Union, and Saudi Arabia — the global expansion phase for ANKTIVA is just beginning. In this ImmunityBio stock analysis, we break down the international rollout strategy, commercial partnerships, revenue trajectory, and what this could mean for IBRX valuation heading into 2026 and beyond.

I use Interactive Brokers to buy most of the stocks I talk about. Create an account and get FREE stocks here: https://ibkr.com/referral/olivier574

Disclaimer
This video is for educational and entertainment purposes only and is not investment advice. I am purely documenting my opinions on companies that interest me. I am not a Financial Advisor and I am not your Financial Advisor. You risk losing your money by investing. Please do your own due diligence and get advice from an expert. I am human and get things wrong.

Tags
$IBRX, IBRX, ImmunityBio stock, immunity bio stock, ImmunityBio, biotech stocks, biotech investing, pharma stocks, pharma investing, pharmaceutical stocks, pharmaceutical investing, biotech news, pharma news